DIGI-INTERNATIONAL
21.6.2022 09:02:08 CEST | Business Wire | Press release
Digi International ® , (NASDAQ: DGII) - a leading global provider of Internet of Things (IoT) connectivity products, solutions, services and wireless data plans - today announced it will showcase a wide range of its new solutions and devices at Embedded World 2022 that enable medical, transportation, agriculture and industrial enterprises to create innovative solutions faster.
Digi’s first-look of its Digi ConnectCore MP1 system-on-modules, Digi ConnectCore Voice Control software, and Digi XBee Intelligent Edge Controller takes place at Bressner Technology booth 1-236 in Hall 1. Digi ConnectCore MP1 is also on display at STMicroelectronics Wall of SOMs booth 4A-148. There are live demos of Digi XBee and its IX15 gateway and the new Digi ConnectCore Voice Control application at the NXP booth 4A-222.
Bolstered by Digi Remote Manager® —the command center of an intelligent network—Digi’s new and smaller embedded IoT technologies dramatically improve the way people, machines and processes interact. Network connectivity is the fundamental key to the true potential of these technologies that place Digi at the forefront of some of the most advanced networking solutions combining software, hardware and services for enterprises.
“This is an exceptionally exciting year to return to Embedded World,” said Andreas Burghart, Senior Product Manager at Digi. “Advances in connectivity and IoT devices are spurring the rapid development of next-generation, cost-effective, integrated solutions. That’s unleashing new waves of innovation across numerous industries that require reliable and secure connectivity. We’re looking forward to sharing our progress and collaborating with our customers on breakthrough embedded solutions.”
Digi’s Embedded World 2022 solution showcase includes three new or recently launched products:
- Digi ConnectCore® MP1 Family – The Digi ConnectCore® MP1 family of system-on-modules (SOMs) features the industry’s smallest STM32MP1 SOM that integrates Wi-Fi, Bluetooth and wired connectivity without comprising design flexibility. The solution also features its Connected Device platform and well-tested development tools and design support. Digi ConnectCore MP1 SOMs offer a cost-effective wireless solution for OEMs seeking to reduce product-development risk and effort.
- Digi ConnectCore Voice Control Software – This advanced voice-control software solution is designed for the acclaimed ConnectCore family of system-on-modules (SOMs). Digi ConnectCore Voice Control is a fully integrated, ready-to use software solution that enables developers to design a voice-based human-machine interface (HMI) to control device operations using speech. It provides voice processing on edge devices (including support for 30 languages and a 60,000-word vocabulary) with no cloud connectivity required. That reduces connectivity costs and data-privacy concerns while providing response times of less than 100ms.
- Digi XBee® Intelligent Edge Controller (IEC) - The Digi XBee® Intelligent Edge Controller (IEC) delivers a comprehensive networking architecture to close the gap between field devices and the cloud and provide powerful asset monitoring and control. In combination with Digi X-ON cloud, the Digi XBee IEC helps companies monitor sensors or remote-control assets over long-range, low-power wide area networks, including LoRaWAN, CAT-M1, and NB-IoT. Industrial devices can be monitored with sub-second latency with alarms and data wirelessly delivered through the Digi X-ON cloud.
At Embedded World, Digi will also demonstrate its wireless IoT solution for smart agriculture with a simulation of a complete ecosystem that can centrally manage multiple farms. This end-to-end solution provides crop managers with real-time weather conditions that help determine optimal irrigation cycles, maximize crop yields and lower labor and supply costs. The heart of the system is the Digi IX15 gateway and cellular router that communicates with irrigation pumps through a wireless mesh network of Digi XBee® modules. Using Digi Remote Manager® and a cloud-based web application, a crop manager monitors exact weather and soil conditions at each farm, and controls individual pumps. The commands pass through the internet to the IX15 by a cellular network, and the IX15 relays the commands to the XBee modules at each pump, turning them on and off remotely.
Digi will also preview its upcoming Digi ConnectCore 93, which includes NXP’s i.MX 93 system-on-a-chip (SOC). Digi is one of six Early Access Partners for this April 2023 release.
For more information about Digi, stop by Bresser Technology Booth 1-236 in Hall 1 or visit: www.digi.com .
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005096/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom